News | May 14, 2024
Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
